Ovarian cancer

Showing 7 of 0 results

• Assessing the cumulative effect of high-risk factors for disease progression and death on real-world progression-free survival (rwPFS) in patients with advanced ovarian cancer (aOC)

  SGO Annual Meeting

  • Publication summary
  • Publications
  • Ovarian cancer
• Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)

  Gynecologic Oncology

  • Real-world evidence
  • Publication summary
  • Publications
  • Comparative effectiveness
  • Ovarian cancer
• Powering a new era of treatment with real-world insights on >29K people with ovarian cancer
  • Real-world evidence
  • Case study
  • Ovarian cancer
• The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

  Cancer

  • Real-world evidence
  • Treatment patterns
  • Comparative effectiveness
  • Ovarian cancer
• Niraparib as first-line maintenance therapy in patients with stage III ovarian cancer and no visible residual disease: AR1ZE real-world study

  Oncology and Therapy

  • Publication summary
  • Publications
  • Ovarian cancer
• The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?

  Poster presented at: ASCO 2024; May 31-June 4, 2024; Chicago, IL

  • Publication summary
  • Publications
  • Ovarian cancer
• Effectiveness of PARP inhibitor maintenance therapy in advanced ovarian cancer by BRCA1/2 and HRD signature in real-world practice

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Comparative effectiveness
  • Drug discovery
  • Ovarian cancer